Integrum appoints Jeffrey S. Zanni as President, U.S.
Mölndal, Sweden, June 16, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan, who has decided to resign from his position.
“Establishing Integrum’s OPRATM Implant System in the U.S. market is our key priority, and Thomas Dugan has made a great contribution in putting all the strategic building blocks in place to deliver long-term growth. We have extensive awareness campaigns, strengthened organization, and a clear reimbursement strategy. We thank Tom for his commitment and dedication and wish him all luck. Going forward, we will focus on commercial execution, and in that shift, I am thrilled to welcome Jeffrey Zanni as our new President, U.S. Jeffrey Zanni is a very experienced commercial orthopedic sales executive who has proven to adapt to new markets and has deep relationships with leading orthopedic surgeons. Under his leadership, our U.S. business will focus on transforming the attention we have from leading hospitals and researchers to increased sales revenues through a broader use of OPRATM Implant System,” comments Rickard Brånemark, CEO of Integrum.
Jeffrey Zanni joins Integrum from Conventus Flower Orthopedics, where he has been Chief Commercial Officer. He has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. Jeffrey Zanni has previously held several executive positions at companies like Vyaire Medical, Tornier Orthopedics Stryker Orthopedics, and Pfizer. Jeffrey Zanni has experience launching new products and developing effective clinician and patient support programs from his previous positions. He has a deep understanding of how to partner with key stakeholders within the U.S. “Integrums OPRATM technology is significantly changing the way we care for amputees. I’m excited to continue building upon the company's success by expanding our market through vision and execution. Integrums technology has opportunity to revolutionize the way patients, surgeons, prosthetists, and caregivers "Feel” about being an amputee and I’m thrilled to be the newest member of the team”, said Jeffrey Zanni, appointed President of Integrum. Jeffrey Zanni will join Integrum on 2023-07-03.
For more information please contact:
Rickard Brånemark, CEO. Phone: +46 708 461061, E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO. Phone: +46 (0) 70 734 96 60, E-mail: jorgen.svanstrom@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.